Medigene is responsible for the clinical development of Veregen®, for which it obtained approval, and which is used in the treatment of genital warts. The ointment is marketed globally by business partners.
Medigene is currently conducting research into the application of AAVLP technology for the treatment of cancer and viral infections, and is examining the possibility of using AAV libraries to systematically identify suitable vaccine candidates.
“We are happy to report solid financial figures and important progress with our marketed drug and development projects for the first nine months of 2013. Revenue from Veregen increases steadily and represents a solid foundation for the company. The preparation of two clinical studies for our drug candidates is on-going.”